A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

May 13, 2024

Study Completion Date

May 13, 2024

Conditions

Healthy Participants

Interventions

DRUG

Baxdrostat

Participants will receive baxdrostat as two separate doses.

DRUG

Placebo

Participants will receive baxdrostat matching placebo.

DRUG

Moxifloxacin

Participants will receive a single dose moxifloxacin

Trial Locations (1)

Research Site, Berlin